Tenaya Therapeutics, Inc. (TNYA) Key Metrics
TNYA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $85.4M
- Enterprise value
- $74.1M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 63.9
- Price / book
- 2.1 10-yr median 1.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.88
TNYA key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTNYA valuation Price multiples at each fiscal year-end price.
TNYA returns How much profit the business earns on the capital it uses.
TNYA per-share figures Results divided by the shares outstanding at year-end.
TNYA financial health Debt, liquidity and how easily interest is covered.
TNYA efficiency & capital use Working capital cycle and where the cash goes.
TNYA valuation history
TNYA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TNYA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TNYA cash returned to shareholders
TNYA price vs earnings per share
TNYA key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $108.8M | $121.3M | $239.1M | — | — | — | — |
| Enterprise value | $19.1M | $73.5M | $146.8M | — | — | — | — |
| Price / book | 0.9 | 1.3 | 1.7 | — | — | — | — |
| Earnings yield | −83.2% | −91.6% | −51.9% | — | — | — | — |
| Free cash flow yield | −63.3% | −75.5% | −43.2% | — | — | — | — |
| Share price at fiscal year-end | $0.71 | $1.43 | $3.24 | $2.01 | $18.95 | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | — | — | — | — |
| Earnings per share | −$0.59 | −$1.31 | −$1.68 | — | — | — | — |
| Operating cash flow per share | −$0.45 | −$1.07 | −$1.38 | — | — | — | — |
| Free cash flow per share | −$0.45 | −$1.08 | −$1.40 | — | — | — | — |
| Cash per share | $0.66 | $0.72 | $1.42 | — | — | — | — |
| Book value per share | $0.81 | $1.09 | $1.89 | — | — | — | — |
| Tangible book value per share | $0.81 | $1.09 | $1.89 | — | — | — | — |
| Capex per share | $0.00 | $0.01 | $0.02 | — | — | — | — |
| Debt per share | $0.07 | $0.16 | $0.17 | — | — | — | — |
| Shares outstanding | 153.0M | 84.8M | 73.8M | — | — | — | — |
| Change in shares outstanding | +80.3% | +15.0% | — | — | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −83.8% | −95.7% | −64.8% | −47.4% | −33.3% | −80.2% | — |
| Return on invested capital (ROIC) | −187.7% | −198.6% | −174.0% | −172.8% | −213.7% | — | — |
| Return on assets (ROA) | −67.9% | −76.5% | −55.2% | −41.5% | −30.0% | −41.2% | −67.8% |
| Return on tangible assets | −61.7% | −92.7% | −72.8% | −44.3% | −22.0% | −25.9% | −67.8% |
| Financial health | |||||||
| Total debt | $10.8M | $13.6M | $12.4M | $15.1M | $15.7M | — | — |
| Cash & short-term investments | $100.5M | $61.4M | $104.6M | $186.5M | $251.3M | $128.5M | $26.6M |
| Net debt | −$89.7M | −$47.8M | −$92.2M | −$171.4M | −$235.6M | −$128.5M | −$26.6M |
| Debt / equity | 0.09 | 0.15 | 0.09 | 0.06 | 0.06 | — | — |
| Debt / assets | 0.07 | 0.11 | 0.07 | 0.05 | 0.05 | — | — |
| Current ratio | 6.84 | 4.22 | 4.91 | 7.99 | 11.73 | 25.78 | 6.73 |
| Quick ratio | 6.84 | 4.22 | 4.91 | 8.81 | 11.73 | 25.78 | 6.73 |
| Interest coverage | — | — | — | — | -1.0 | — | — |
| Working capital | $90.2M | $51.4M | $88.8M | $169.5M | $233.6M | $124.9M | $23.6M |
| Invested capital | $33.5M | $45.0M | $47.2M | $71.9M | $42.9M | $10.9M | −$70.4M |
| Tangible asset value | $123.3M | $92.9M | $139.4M | $243.4M | $278.5M | $139.4M | −$43.7M |
| Net current asset value | $81.9M | $40.3M | $80.5M | $158.2M | $217.2M | $121.2M | −$54.0M |
| Graham net-net per share | $0.50 | $0.41 | $1.00 | — | — | — | — |
| Capital allocation | |||||||
| Share buybacks (net) | — | — | — | $0 | $13,000 | $1,000 | $3,000 |
| Capex / depreciation | 0.07 | 0.12 | 0.14 | 3.19 | 8.48 | 3.93 | 1.47 |
| Efficiency | |||||||
| Days of inventory on hand | — | — | — | -835.7 | — | — | — |
| Days payables outstanding | 189.1 | 232.6 | 319.5 | 425.2 | 532.2 | 118.8 | 110.1 |
| Receivables turnover | — | — | — | 0.00 | — | — | — |
| Payables turnover | 1.93 | 1.57 | 1.14 | 0.86 | 0.69 | 3.07 | 3.31 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | $2.2M | — | — | — |
| Average payables | $4.4M | $5.4M | $7.6M | $10.1M | $5.9M | $808,500 | $600,000 |
| Average inventory | — | — | — | −$19.9M | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from TNYA's annual financial statements (latest annual report filed March 11, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TNYA valuation and financial ratios
Tenaya Therapeutics earned a return on equity of −83.8% and a return on invested capital of −187.7% in fiscal 2025. It ended the year with $10.8 million of debt and $100.5 million in cash and short-term investments, a net cash position of $89.7 million.
See the TNYA income statement, the TNYA chart for price history, or the TNYA stock overview for the latest quote and news.
TNYA key metrics FAQ
What is Tenaya Therapeutics's return on equity?
Tenaya Therapeutics's return on equity (ROE) was −83.8% in fiscal 2025: net income of -$90.6 million on average shareholders' equity of $108.1 million.
What is Tenaya Therapeutics's ROIC?
Tenaya Therapeutics's return on invested capital was −187.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Tenaya Therapeutics have?
Tenaya Therapeutics had total debt of $10.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.09 and more cash than debt.
What is Tenaya Therapeutics's free cash flow yield?
Tenaya Therapeutics generated -$68.9 million of free cash flow in fiscal 2025, a free cash flow yield of −63.3% on its market value at year-end ($108.8 million).
What is Tenaya Therapeutics's current ratio?
Tenaya Therapeutics's current ratio was 6.84 at the end of fiscal 2025: current assets were 6.84 times current liabilities.